Search

Pucotenlimab

It received its first global approval in China in July 2022 for the treatment of solid tumours.[A257296] It is being investigated in other cancers.

8-chlorotheophylline

Because adenosine causes a decrease in neuronal firing, blockade of the adenosine receptor causes the reverse effect resulting in excitation. … Its main use is in combination with [Diphenhydramine] as the antiemetic drug [Dimenhydrinate].

C31G

is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment in

Rebaudioside A

Rebaudioside A is under investigation in clinical trial NCT03510624 (Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus).

Rocaglamide

[didesmethylrocaglamide]) are currently being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas, and carcinomas, as well as adjuvant therapy in the treatment of … [A186796] Reports of _Aglaia_ anti-tumor activity date back as far as 1973, and rocaglamide-A was first isolated in 1982 from the species _A. elliptifolia_.

Loteprednol

Loteprednol is a corticosteroid. A more commonly used formulation of loteprednol is its ester, loteprednol etabonate.

XL019

An IND for XL019 was filed by Exelixis in May 2007.

Pozelimab

autoimmune hemolysis that are often observed in CHAPLE disease. … CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US.

INGN 225

INGN 225 is currently in Phase 1/2 trials in patients with small cell lung cancer and breast cancer. … INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53.

Latiglutenase